Zobrazeno 1 - 6
of 6
pro vyhledávání: '"R. Nätkin"'
Autor:
S. Taavitsainen, N. Engedal, S. Cao, F. Handle, A. Erickson, S. Prekovic, D. Wetterskog, T. Tolonen, E. M. Vuorinen, A. Kiviaho, R. Nätkin, T. Häkkinen, W. Devlies, S. Henttinen, R. Kaarijärvi, M. Lahnalampi, H. Kaljunen, K. Nowakowska, H. Syvälä, M. Bläuer, P. Cremaschi, F. Claessens, T. Visakorpi, T. L. J. Tammela, T. Murtola, K. J. Granberg, A. D. Lamb, K. Ketola, I. G. Mills, G. Attard, W. Wang, M. Nykter, A. Urbanucci
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Identifying the molecular mechanisms of response to systemic therapy in prostate cancer remains crucial. Here, the authors apply single cell-ATAC and RNAseq to models of early treatment response and resistance to enzalutamide and identify chromatin a
Externí odkaz:
https://doaj.org/article/cc3e718f606845d686441f42a30442e4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hermelo I; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland. ismail.hermelo@gmail.com.; Tays Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland. ismail.hermelo@gmail.com.; Department of Neurosurgery, Tampere University Hospital, Tampere, Finland. ismail.hermelo@gmail.com., Virtanen T; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.; Tays Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland., Salonen I; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.; Tays Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland., Nätkin R; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.; Tays Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland., Keitaanniemi S; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.; Tays Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland., Tiihonen AM; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.; Tays Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland., Lehtipuro S; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.; Tays Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland., Kummola L; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Raulamo E; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland., Nordfors K; Unit of Pediatric Haematology and Oncology, Tampere University Hospital, Tampere, Finland.; Tays Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland., Haapasalo H; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.; Fimlab Laboratories Ltd, Tampere University Hospital, Tampere, Finland., Rauhala M; Tays Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland.; Department of Neurosurgery, Tampere University Hospital, Tampere, Finland., Kesseli J; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.; Tays Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland., Nykter M; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland.; Tays Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland., Haapasalo J; Tays Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland.; Department of Neurosurgery, Tampere University Hospital, Tampere, Finland., Rautajoki K; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland. kirsi.rautajoki@tuni.fi.; Tays Cancer Center, Tampere University Hospital and Tampere University, Tampere, Finland. kirsi.rautajoki@tuni.fi.; Tampere Institute for Advanced Study, Tampere University, Tampere, Finland. kirsi.rautajoki@tuni.fi.
Publikováno v:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 Jan 03; Vol. 74 (2), pp. 63. Date of Electronic Publication: 2025 Jan 03.